Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. - Wikidata - wikimedia - TriplyDB

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.

http://www.wikidata.org/entity/Q33308740

about

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer MEK1 mutations confer resistance to MEK and B-RAF inhibition.The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.Differential regulation of Smad3 and of the type II transforming growth factor-β receptor in mitosis: implications for signaling PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin.MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.Multiplexed tracking of combinatorial genomic mutations in engineered cell populations.Genomic complexity and AKT dependence in serous ovarian cancer.MEK genomics in development and disease OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES.Genetics of melanoma MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.In vivo severity ranking of Ras pathway mutations associated with developmental disorders.Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.Mechanisms of aneuploidy induction by RAS and RAF oncogenes Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development Allosteric modulators of MEK1: drug design and discovery.Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms.Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation.Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia.Pathogenetics of the RASopathies.Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model.VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations.The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants Intrinsically active MEK variants are differentially regulated by proteinases and phosphatases

P2860

Q24650026-7A4BD965-7033-4986-9C8C-A98975644A8E Q27777362-78DE644B-D2A6-4F0A-8F3B-2E297FD7A9FF Q28744228-CD055DA8-2B85-4AEB-8894-AC9433B5DD42 Q33588267-64B6F1F1-A925-4D1A-B1DE-493D0A611B24 Q33778184-733C8ACD-4D04-46D8-9012-05D43EBA6713 Q34395698-51D2BBCC-0DDF-477C-8EA0-5E0DE2EDB024 Q34436731-581DDD64-3BCB-4E1B-82E0-10F98E312E70 Q34690325-25E5D1A2-7928-48AE-83CA-CE79ED7331B1 Q34887145-CB07F310-5456-41C0-BC44-46A3AC749CD6 Q35462978-857E83F6-3A7F-4D71-8D69-F8165EFD986F Q35583838-DCF5CA7A-1BFD-425E-A06D-0935E8E8AB67 Q35743316-AEC7C5BA-C008-4DB5-8F25-93DB5CA28238 Q36099005-51EB0702-F369-4B0A-B44B-5001F16C8B27 Q36460902-396B2D6D-83E5-4541-AFCB-254162C1E52C Q36563659-76E2D147-FDDE-4CB8-BCEA-D4E3D5F37560 Q36586093-99FF78C3-76DF-4E1D-B07A-1F9D9356D334 Q36813976-6E7B37E0-DB5F-47AC-838A-D45EDB626728 Q36862768-7B4255EC-F6DB-4CAA-A04E-F4DC78CDADDA Q36980836-CE8A2C65-8717-41C7-A874-A2256498CD97 Q37343475-BD57A57E-AFC7-4950-81A6-821062A08330 Q37599060-9D521398-1129-4A5C-A030-5B32C96C9D43 Q37624361-DB692F59-F1D2-4D0C-B22C-8AC58AE6A6AA Q37948057-6BB162FE-3084-4382-930A-A767EE8B5FB3 Q38487106-2E389243-50EA-4B4A-B072-769E6831F5CD Q38817910-7B47A867-4959-4895-B5ED-938772C28240 Q39411958-E43BBCD5-282C-4CBB-A394-59D19937649A Q40443186-7D58BFC7-3B86-44F6-92F4-7B11BBD082D6 Q42774672-9AEE5B18-E332-42EE-BE08-3F102D7079D6 Q43244288-9651E487-DD8D-4FCA-BB64-5A495DFFBC49 Q45957290-ABA8B2A0-55F9-4E7A-B0E7-0B601E50BE90 Q47619786-7E1F1F89-4047-4BB4-BC7B-E14BC2C3A3F6 Q50794794-BA40E9D8-E432-4646-B8B5-2CC5212B03DC Q51911662-C9D23F77-990C-412D-9F25-E3528189A0BA Q58056531-1681AACC-EC4B-45FD-AEFC-2A52D7BA1354 Q58428561-3CC0872B-CC75-4012-B39B-164E82B7F9A9

P2860

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.

http://www.wikidata.org/entity/Q33308740

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@ast

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@en

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@nl

type

label

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@ast

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@en

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@nl

prefLabel

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@ast

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@en

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@nl

P1433

Q33308740-BFA5AB81-58D4-423D-BF4B-81773B2DAF91

P1476

Q33308740-1C2A781C-635E-4D26-AF45-328CE7BCDD53

P2093

Q33308740-23B16B98-8BF6-43ED-B6AA-C1D221D536A5

Q33308740-3D348F01-90FA-4D17-83B0-225F45D7BCCE

Q33308740-8CF73626-07E5-4C76-8951-68D6505A36E0

Q33308740-F69FFDBE-D851-4AAE-ADEE-C16B9739BA8F

P2860

Q33308740-0CC74116-42B5-48B6-ADE9-EE90019D10D0

Q33308740-1014B339-6AD8-4BCD-AA0D-A4C9305D6FD9

Q33308740-11790C93-84F0-4FDB-982E-EDF522418858

Q33308740-1638782C-EC10-47FA-BB24-1DCB57FCCD39

Q33308740-1D31CEFB-BC53-4ACF-8077-E613B6FFB1EF

Q33308740-1E84B071-425F-42F8-AFBE-D6FBA30E542E

Q33308740-1F2383D3-DC96-4307-B047-A6B0F6D1169E

Q33308740-22206C9A-D779-4DF4-A9A1-2AFC6E7798FE

Q33308740-2D153507-6A9C-4053-8D86-849E421E25BF

Q33308740-3D452A9B-D7CC-4347-B396-7D810B8BC462

P304

Q33308740-ECD94FA1-DEA8-4CE3-A916-0C41903F37E3

P31

Q33308740-C7066E83-1446-4C4C-85EE-76E48F208468

P356

Q33308740-1564B8CC-67CA-4707-B566-8AF51F5F6D22

P407

Q33308740-FAC96549-1E9B-426F-8D4C-AC5E3F729307

P433

Q33308740-3D6C96E2-D60B-4A96-8D0F-FA39A57FB32B

P478

Q33308740-A283EE6C-83C9-403F-A439-F0D4ACC11B51

P577

Q33308740-6CB5C568-4DDE-4012-96E2-EE7A4AEDD803

P5875

Q33308740-B29AD5FC-6EC1-407A-9FD2-413CB1084085

P698

Q33308740-0592BAC4-A4D7-42F9-9285-7A9B9FAD9C62

P921

Q33308740-D5032A2F-5447-4FD5-8C4E-83A849D4A9FC

P932

Q33308740-0E2A5FFC-308A-4169-9F33-11492F5DC782

P356

JOURNAL.PONE.0001279

P1433

P1476

Mutation analysis of BRAF, MEK ...... nes: implications for therapy.

@en

P2093

Anne L Estep

http://www.w3.org/2001/XMLSchema#string

Chana Palmer

http://www.w3.org/2001/XMLSchema#string

Frank McCormick

http://www.w3.org/2001/XMLSchema#string

Katherine A Rauen

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of the BRAF gene in human cancer

Predicting the effects of amino acid substitutions on protein function

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

SIFT: Predicting amino acid changes that affect protein function

Cancer statistics, 2007

BRAF mutation predicts sensitivity to MEK inhibition

The RAF proteins take centre stage

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

P304

e1279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0001279

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5788291

http://www.w3.org/2001/XMLSchema#string

P698

18060073

http://www.w3.org/2001/XMLSchema#string

P921

P932

2093994

http://www.w3.org/2001/XMLSchema#string